UBS Group AG Has $50.46 Million Position in Vaxcyte, Inc. $PCVX

UBS Group AG increased its stake in Vaxcyte, Inc. (NASDAQ:PCVX) by 29.0% in the 4th quarter, Holdings Channel reports. The firm owned 1,093,593 shares of the company’s stock after purchasing an additional 246,020 shares during the period. UBS Group AG’s holdings in Vaxcyte were worth $50,458,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in PCVX. Universal Beteiligungs und Servicegesellschaft mbH increased its position in Vaxcyte by 105.3% in the 4th quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 70,124 shares of the company’s stock worth $3,236,000 after buying an additional 35,974 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Vaxcyte by 3.2% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 40,002 shares of the company’s stock worth $1,846,000 after buying an additional 1,253 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its position in Vaxcyte by 6.0% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 24,579 shares of the company’s stock worth $1,134,000 after buying an additional 1,395 shares during the period. CWM LLC increased its position in Vaxcyte by 9.0% in the 4th quarter. CWM LLC now owns 2,840 shares of the company’s stock worth $131,000 after buying an additional 234 shares during the period. Finally, Signaturefd LLC increased its position in Vaxcyte by 20.0% in the 4th quarter. Signaturefd LLC now owns 6,167 shares of the company’s stock worth $285,000 after buying an additional 1,028 shares during the period. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Vaxcyte Price Performance

Shares of PCVX stock opened at $55.60 on Wednesday. The stock’s fifty day simple moving average is $58.67 and its 200 day simple moving average is $51.67. The firm has a market cap of $8.03 billion, a price-to-earnings ratio of -9.89 and a beta of 1.30. Vaxcyte, Inc. has a one year low of $28.09 and a one year high of $65.00.

Vaxcyte (NASDAQ:PCVX) last announced its quarterly earnings results on Tuesday, February 24th. The company reported ($1.80) EPS for the quarter, missing the consensus estimate of ($1.46) by ($0.34). During the same quarter last year, the business earned ($1.12) earnings per share. On average, research analysts anticipate that Vaxcyte, Inc. will post -7 earnings per share for the current year.

Analyst Upgrades and Downgrades

PCVX has been the topic of several recent analyst reports. Needham & Company LLC lifted their price target on Vaxcyte from $90.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday, January 7th. Jefferies Financial Group reaffirmed a “buy” rating on shares of Vaxcyte in a research report on Tuesday, March 10th. Guggenheim restated a “buy” rating and set a $116.00 price objective on shares of Vaxcyte in a research report on Monday, February 2nd. BTIG Research boosted their price objective on Vaxcyte from $85.00 to $89.00 and gave the company a “buy” rating in a research report on Wednesday, February 25th. Finally, Wall Street Zen cut Vaxcyte from a “sell” rating to a “strong sell” rating in a research report on Tuesday, April 28th. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $86.00.

Insider Buying and Selling at Vaxcyte

In related news, CAO Elvia Cowan sold 3,000 shares of the business’s stock in a transaction on Tuesday, April 7th. The stock was sold at an average price of $60.00, for a total value of $180,000.00. Following the sale, the chief accounting officer owned 28,975 shares of the company’s stock, valued at $1,738,500. The trade was a 9.38% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Jim Wassil sold 2,250 shares of the business’s stock in a transaction on Friday, May 1st. The shares were sold at an average price of $56.83, for a total value of $127,867.50. Following the completion of the sale, the chief operating officer directly owned 160,744 shares in the company, valued at approximately $9,135,081.52. This represents a 1.38% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders sold 17,037 shares of company stock worth $994,899. 3.10% of the stock is owned by insiders.

Vaxcyte Profile

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.